MEDICINES FORMULARY JANUARY This version supersedes all previous versions for Medicines Formulary

Size: px
Start display at page:

Download "MEDICINES FORMULARY JANUARY This version supersedes all previous versions for Medicines Formulary"

Transcription

1 EDICIES FORULARY JAUARY 2017 This version supersedes all previous versions for edicines Formulary

2 olicy title edicines Formulary olicy HA05 reference olicy category harmacy Relevant to All staff handling medicines Date published January 2017 Implementation January 2017 date Date last January 2017 reviewed ext review Following DTC formulary decisions as and when applicable date olicy lead Chief harmacist Contact details Accountable director Approved by (Group/Comm): Ratified by (Committee): Document history Telephone: Dr Vincent Kirchner, edical Director Drug and Therapeutics Committee December 2016 Date Version Summary of amendments Jan ew inclusion / amendment Dec ew inclusion Dec ew inclusion Sep Removal Apr Review of approvals Feb ew inclusions / removal Sep ew inclusions ar ew inclusions ov ew inclusions July ew inclusions Apr ICE compliance Feb ICE compliance ov Full review, ICE compliance, scope of practice embership of the policy development/ review team Lucy Reeves, Chief harmacist Lead harmacists TRUST EDICIES FORULARY_HA05_January 2017_V13

3 Consultation Drug and Therapeutics Committee DO OT AED THIS DOCUET Further copies of this document can be found on the Foundation Trust intranet. TRUST EDICIES FORULARY_HA05_January 2017_V13

4 Camden & Islington HS Foundation Trust edicines Formulary edicines Formulary olicy The formulary is a list of medicines approved for use (BF limits) within the Trust. The process for introducing medicines onto the Trust formulary is documented in the Trust edicines Formulary olicy. The C&I FT formulary applies only to psychiatric medicines. All physical medicines should adhere to local acute trust and primary care policies and procedures. For medicines not included in this list refer to the edicines Formulary olicy (Section 7: Use of non-formulary medicines). Refer to the Trust edicines anagement olicy (Appendix 5: olicy for the off-label use of medicines and unlicensed medicines) for further information on unlicensed medicines (UL) and off-label uses and the approval process. Independent on edical rescribers: Scope of practice edicines that have been approved for prescribing by Independent on edical rescribers, authorised to practice within the Trust, are annotated. Independent prescribing must be within the limits of the Trust on edical rescribing olicy, which is for patients with an existing diagnosis who have been seen by the Consultant within the last year and must be within their scope of practice. Independent on edical rescribers working in Addiction Services may only prescribe medicines listed within the Drugs used in substance dependence section of the formulary. Independent on edical rescribers may only prescribe medicines listed for nicotine dependence within the Drugs used in substance dependence section. rescribing and Treatment Guidelines This is not a guideline and does not make recommendations about treatment. Reference should be made to the Trust treatment guidelines on Trustnet or the current edition of audsley & Oxleas rescribing Guidelines. lease consult the current BF for prescribing information and/or the Summary of roduct Characteristics (SC) for the respective medicine, available at The formulary list below generally follows the BF categorisation system. Approved unlicensed medicines and off-label use of medicines are annotated where appropriate. TRUST EDICIES FORULARY_HA05_January 2017_V13

5 British ational Formulary: Chapter CETRAL ERVOUS SYSTE 4.1 Hypnotics and Anxiolytics Hypnotics Benzodiazepines Temazepam CD Tablet 10mg, 20mg Oral solution 10mg/5ml Approved (2 nd line option): insomnia (short term use) Trust guidance/policy: Guidelines for the anagement of Insomnia; Controlled Drug policy ICE(TA77) Z drugs Zopiclone Tablet 3.75mg, 7.5mg Approved (1 st line option): insomnia (short term use) Zolpidem tartrate Tablet 5mg, 10mg Approved (3 rd line option): insomnia (short term use) Antihistamine romethazine Tablets, elixir Approved pregnant women elatonin receptor agonist elatonin R tablets (licensed) Tablets, oral solution (unlicensed) Approved restricted use: Sleep disorders in patients with learning disabilities (off label indication) Trust guidance/policy: Guidelines for the anagement of Insomnia; ICE(TA77) Trust guidance/policy: Guidelines for the anagement of Insomnia; ICE(TA77) ICE CG 192 ICE G11 (CL JFC approved) Anxiolytics Benzodiazepines BF section Chlordiazepoxide Capsules 5mg, 10mg Approved: anxiety (short term use); alcohol withdrawal (section 4.10) Clonazepam Tablet 500microgram, 2mg Liquid 500microgram/5ml, 2mg/5ml Approved: off-label use anxiety (short term) TRUST EDICIES FORULARY_HA05_January 2017_V13

6 Diazepam Lorazepam Tablet 2mg, 5mg,10mg Oral solution 2mg/5ml, 5mg/5ml Tablet 1mg Injection 4mg/ml Approved (1 st line option): anxiety (short term use); alcohol withdrawal (section 4.10) Approved (1 st line option): anxiety (short term use); off-label use for treatment of acute phase of mania and aggression / rapid tranquilisation Trust guidance: Rapid Tranquilisation guidelines ICE(CG25) Buspirone Buspirone hydrochloride Tablet 5mg, 10mg Approved: anxiety (short term use) Beta-blockers BF section 2.4 ropranolol Tablet 10mg, 40mg Approved: Autonomic symptoms of anxiety Antidepressants AOI Citalopram* Fluoxetine* aroxetine Sertraline* Venlafaxine (Escitalopram) henelzene* oclobemide See section 4.3 See section 4.3 Approved (1 st /2 nd line option): (off-label*) use in generalised anxiety disorder (GAD) and panic disorder; (1 st / 2 nd line option) social anxiety disorder (B. Escitalopram may only be prescribed for social anxiety disorder and only if other SSRIs not appropriate) Approved (3 rd line option): (off-label*) use in social anxiety disorder ICE(CG113) ICE(CG159) ICE(CG159) Antiepileptic BF section regabalin See section 4.3 Approved (3 rd line option): treatment of GAD, where either two SSRIs or one SSRI and an SRI have been tried and failed or not tolerated Higher cost preparation rescribe as twice daily dosing regime. Caution: risk of misuse in SS/prison services ICE(CG113) Antihistamine BF section romethazine Injection 25mg/ml Tablets, liquid Approved (2 nd line option): off-label use for treatment of acute phase of mania and aggression / rapid tranquilisation Trust guidance: Rapid Tranquilisation guidelines 4.2 Drugs used in psychosis and related disorders TRUST EDICIES FORULARY_HA05_January 2017_V13

7 4.2.1 Antipsychotic drugs Typical antipsychotics Benperidol Tablets 250microgram Approved - Restricted use: Control of deviant antisocial sexual behaviour Chlorpromazine Flupentixol Haloperidol Sulpiride Trifluoperazine hydrochloride Tablet 25mg, 50mg, 100mg Oral solution 25mg/5ml, 100mg/5ml Tablet 3mg See section for depot preparation Tablet 500microgram, 1.5mg, 5mg, 10mg Capsule 500 microgram Oral liquid 1mg/ml, 2mg/ml Injection 5mg/ml See section for depot preparation Tablet 200mg. 400mg Oral solution 200mg/5ml Tablet 1mg, 5mg Oral solution 5mg/5ml Approved: schizophrenia and related psychoses; mania; short term adjunctive management of psychomotor agitation, excitement and violent or dangerously impulsive behaviour; Approved: schizophrenia and other psychoses; depression (BF section 4.3.4) Approved: schizophrenia and other psychoses; mania; short term adjunctive management of psychomotor agitation, excitement and violent or dangerously impulsive behaviour; short term adjunctive management of severe anxiety. Approved: schizophrenia Approved: schizophrenia and other psychoses; short term adjunctive management of psychomotor agitation, excitement and violent or dangerously impulsive behaviour Approved: schizophrenia and other psychoses Trust guidance: Antipsychotic rescribing guidelines; Rapid Tranquilisation guidelines Should never be given parenterally due to risk of severe hypotension and prolonged unconsciousness, plus reported association of high doses with sudden death. Also extremely painful parenterally. ICE(CG82) Trust guidance: Antipsychotic rescribing guidelines ICE(CG82) Trust guidance: Antipsychotic rescribing guidelines; Rapid Tranquilisation guidelines ICE(CG82); (CG25) Trust guidance: Antipsychotic rescribing guidelines ICE(CG82) Trust guidance: Antipsychotic rescribing guidelines ICE(CG82) Zuclopenthixol Tablet 2mg, 10mg, 25mg Trust guidance: Antipsychotic dihydrochloride rescribing guidelines ICE(CG82) Zuclopenthixol Injection 50mg/ml, Approved: short term management of acute Trust guidance: Antipsychotic TRUST EDICIES FORULARY_HA05_January 2017_V13

8 acetate (Clopixol Acuphase ) 100mg/2ml See section for depot preparation zuclopenthixol deconoate psychoses, mania or exacerbations of chronic psychoses rescribing guidelines; Clopixol Acuphase guideline; Rapid Tranquilisation guidelines ICE(CG25) Atypical antipsychotics Amisulpride Aripiprazole Clozapine Tablet 50mg, 100mg, 200mg, 400mg Solution 100mg/ml Tablets 5mg, 10mg,15mg Orodispersible tablets 10mg, 15mg Injection 7.5mg/ml (9.75mg vial) Tablet 25mg, 100mg (Clozaril ) Approved: schizophrenia; off-label use in psychoses Off-label use for short term treatment of persistent aggression in moderate to severe Alzheimer s dementia where risk of harm to self & others; Approved: schizophrenia; treatment & recurrence prevention of mania Off-label use for short term treatment of persistent aggression in moderate to severe Alzheimer s dementia where risk of harm to self & others. Adjunctive treatment in depression Approved: control of agitation & disturbed behaviour in schizophrenia Approved: schizophrenia (unresponsive to, or intolerant of conventional antipsychotics) Trust guidance: Antipsychotic rescribing guidelines Short term use only in Alzheimer s Disease & to be reviewed regularly ICE(CG82) Trust guidance: Antipsychotic rescribing guidelines. Short term use only in Alzheimer s Disease & to be reviewed regularly higher cost ICE(CG82); (CG90) Trust guidance:; Rapid Tranquilisation guidelines Antipsychotic rescribing guidelines Trust guidance/policy: Antipsychotic rescribing guidelines; Initiating clozapine in the community policy; Clozapine red result policy; Clozapine therapeutic drug monitoring; Clozaril tablets: atient, prescriber and supplying pharmacy must be registered with the Clozaril atient onitoring Service (CS) Liquid suspension 50mg/ml (Denzapine ) amed patient only via on formularly request form: Denzapine suspension only ICE(CG82) Denzapine suspension: atient, prescriber and pharmacy TRUST EDICIES FORULARY_HA05_January 2017_V13

9 licensed preparation available. must be registered with Denzapine atient onitoring Service (DS). Olanzapine Quetiapine Tablet 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg Orodispersible tablet 5mg, 10mg, 15mg,20mg Injection (Zyprexa ) 10mg/2ml vial Tablet 25mg, 100mg, 150mg, 200mg, 300mg odified release tablet 50mg, 200mg, 300mg,400mg Approved: schizophrenia; treatment & recurrence prevention of mania; control of agitation & disturbed behaviour in schizophrenia or mania; off-label use in psychoses Off-label use for short term treatment of persistent aggression in moderate to severe Alzheimer s dementia where risk of harm to self & others. Adjunctive treatment in depression ot Approved Approved: schizophrenia; treatment and prevention of mania and depression in bipolar disorder; Off-label use for short term treatment of persistent aggression in moderate to severe Alzheimer s dementia where risk of harm to self & others. Adjuntive treatment in depression (IR formulation approved for off-label use) Trust guidance: Antipsychotic rescribing guidelines Short term use only in Alzheimer s Disease & to be reviewed regularly ICE(CG82); (CG25); (CG90) Trust guidance: Antipsychotic rescribing guidelines Instant release tablets should be prescribed. /R tablets: Higher cost - only use where specifically required (prescribe as R tablets ) ICE(CG82); (CG90) Risperidone Tablet 500microgram, 1mg, 2mg, 3mg, 4mg, 6mg Orodispersible tablet 500microgram, 1mg, 2mg, 3mg, 4mg Liquid 1mg/ml See section for depot preparation Approved 1 st line option: acute & chronic psychoses; mania; short term treatment of persistent aggression in moderate to severe Alzheimer s dementia where risk of harm to self & others; short term treatment of persistent aggression in conduct disorder. Adjuctive treatment in depression. Trust guidance: Antipsychotic rescribing guidelines Short term use only in Alzheimer s Disease & to be reviewed regularly: Only licensed for short term (6 weeks) treatment of persistent aggression in Alzheimer s dementia / conduct disorder. ICE(CG82); (CG25); (CG90) TRUST EDICIES FORULARY_HA05_January 2017_V13

10 4.2.2 Antipsychotic depot injections Depot antipsychotics typicals Flupentixol decanoate Fluphenazine decanoate Haloperidol decanoate Zuclopenthixol decanoate Injection 20mg/ml (1ml, 2ml amp) Injection (Depixol conc ) 100mg/ml (0.5ml, 1ml amp) Injection (Depixol Low Volume ) 200mg/ml Injection 25mg/ml (0.5ml, 1ml amp) Injection (odecate conc ) 100mg/ml (0.5ml,1ml amp) Injection 50mg/ml, 100mg/ml Injection 200mg/ml Injection (Clopixol conc ) 500mg/ml Approved (1 st line option): maintenance in schizophrenia and other psychoses Approved (1 st line option): maintenance in schizophrenia and other psychoses Approved (1 st line option): maintenance in schizophrenia and other psychoses Approved (1 st line option): maintenance in schizophrenia and other psychoses Trust guidance: Depot antipsychotic medication guidelines; Antipsychotic rescribing guidelines ICE(CG82) Trust guidance: Depot antipsychotic medication guidelines; Antipsychotic rescribing guidelines ICE(CG82) Trust guidance: Depot antipsychotic medication guidelines; Antipsychotic rescribing guidelines ICE(CG82) Trust guidance: Depot antipsychotic medication guidelines; Antipsychotic rescribing guidelines ICE(CG82) Depot antipsychotics - atypicals Aripiprazole long acting injection Risperidone long acting injection aliperidone long acting injection (monthly) Injection 400mg Injection 25mg, 37.5mg, 50mg Injection 50 mg, 75 mg, 100 mg, 150 mg Approved: maintenance treatment of schizophrenia and other psychoses in patients stabilised with oral aripiprazole Approved: maintenance in schizophrenia and other psychoses in patients tolerant to risperidone orally Approved- Restricted Use; treatment of adults with schizophrenia and in patients that have a documented response and tolerability to risperidone. Trust guidance: Depot antipsychotic medication guidelines; Antipsychotic rescribing guidelines ICE(CG82) Trust guidance: Depot antipsychotic medication guidelines; Antipsychotic rescribing guidelines ICE(CG82) aliperidone oral tablets are OT approved for use in C&I. Typical antipsychotic depots should be considered prior to TRUST EDICIES FORULARY_HA05_January 2017_V13

11 aliperidone prolonged release suspension for injection (three monthly) Injection 175 mg, 263 mg, 350 mg, 525 mg ay only be initiated by a consultant, on completion of non-formulary form. Approved- Restricted Use; for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1- monthly paliperidone palmitate injectable product ay only be initiated by a consultant, on completion of an non-formulary form. initiating paliperidone palmitate due to the significant financial implications. aliperidone is the active metabolite of risperidone. It has not demonstrated greater efficacy over other antipsychotics. ICE(CG82) Reserved for patients unable to comply with monthly injections and susceptible to relapse. Olanzapine Embonate ot Approved Antimanic Drugs Benzodiazepines See section Approved: Off label use for treatment of BF section acute phase of mania. Diazepam Chlordiazepoxide Lorazepam Clonazepam idazolam Should not be used for long periods because of risk of dependence. ICE(CG185) Antipsychotics BF section Haloperidol Olanzapine Quetiapine Risperidone Aripiprazole See section Approved: treatment of mania; Olanzapine & aripiprazole are also licensed for prevention in patients whose manic episode responded to the respective drug Aripiprazole higher cost ICE(CG185) Lithium Lithium carbonate Tablet (riadel ) 200mg, 400mg Approved: treatment and prophylaxis of mania, bipolar disorder and recurrent ust be prescribed by brand. reparations vary widely in TRUST EDICIES FORULARY_HA05_January 2017_V13

12 Lithium citrate Liquid (riadel) 520mg/5ml (5ml = 204mg lithium carbonate) Liquid (Li-liquid) 509mg/5ml (5ml = 200mg lithium carbonate) depression bioavailablity: changing preparations requires the same precautions as initiation of treatment. ote: lithium carbonate 200mg = lithium citrate 509mg ICE(CG185) Lamotrigine Sodium valproate Semisodium valproate (Depakote ) Tablet 25mg, 50mg, 100mg, 200mg Dispersible tablet 5mg, 25mg, 100mg Tablet crushable 100mg Tablet e/c 200mg, 500mg Tablet R 200mg, 300mg, 500mg Liquid 200mg/5ml Approved: Off-label treatment and prophylaxis of depressive episode in BAD Approved: Off-label use in bipolar affective disorder (BAD). ICE(CG185) ICE(CG185) Tablet e/c 250mg, 500mg ot Approved Higher cost preparation 4.3 Antidepressant Drugs Tricyclic and related antidepressant drugs Tricyclic antidepressants Amitriptyline hydrochloride Clomipramine hydrochloride Imipramine hydrochloride Tablet 10mg, 25mg, 50mg Liquid 25mg/ml Capsules 10mg, 25mg, 50mg Tablet 10mg, 25mg Approved: Depression Approved: Depression, phobic & obsessional states, off-label use panic disorder Approved: Depression; off label use panic disorder Lofepramine Tablet 70mg Approved: Depression TRUST EDICIES FORULARY_HA05_January 2017_V13 Amitriptyline particularly dangerous in overdose 1 ICE(CG90);(CG91);(CG38) ICE(CG90);(CG91);(CG38); (CG113) ICE(CG90);(CG91);(CG38); (CG113)

13 Liquid 70mg/5ml ICE(CG90);(CG91);(CG38) Related antidepressants ianserin hydrochloride Tablet 10mg, 20mg, 30mg Approved: Depression Trazadone Tablets, Liquid Approved: Depression See BF advice regarding blood monitoring before prescribing ICE(CG90);(CG91);(CG38) onoamine-oxidase Inhibitors (AOIs) AOIs henelzine Tablet 15mg Approved: Depression, social anxiety disorder (off label) Less suitable for prescribing due to dangers of dietary & drug interactions ICE(CG90);(CG91);(CG38) (CG 159) Reversible AOIs oclobemide Tablet 150mg, 300mg Approved: Depression, social anxiety disorder ICE(CG90);(CG91);(CG38) (CG159) Selective Serotonin Re-uptake Inhibitors (SSRIs) SSRIs Citalopram Tablet 10mg, 20mg, 40mg Fluoxetine Liquid (Cipramil oral drops) 40mg/ml Capsule 20mg Liquid 20mg/5ml Approved (1 st line option*): Depression; panic disorder; off-label use in generalised anxiety disorder (GAD) Approved (1 st line option): Depression; bulimia nervosa; obsessive-compulsive *Associated with dose related QT prolongation, therefore avoid in specific patient groups see BF. 4 drops (8mg) Cipramil oral drops is equivalent in therapeutic effect to 10mg citalopram tablet. ICE(CG90/91);(CG91);(CG38); (CG113) ICE(CG90/91);(CG91);(CG38); TRUST EDICIES FORULARY_HA05_January 2017_V13

14 disorder (OCD); off-label use in GAD aroxetine Tablet 10mg, 20mg, 30mg Approved: Depression; OCD; panic Liquid 10mg/5ml disorder; social anxiety disorder; TSD, offlabel use in GAD Sertraline Tablet 50mg, 100mg Approved (1 st line option): Depression; OCD; panic disorder; social anxiety disorder; TSD, off-label use in GAD (CG113) ICE(CG90);(CG91);(CG38); (CG113) (CG159) ICE(CG90);(CG91);(CG38); (CG113) (CG159) Other antidepressant drugs Antipsychotic Flupentixol Tablet 500microgram, 1mg 3mg Approved: depression; psychoses (see BF section 4.2.1) ICE(CG90)(CG91) resynaptic alpha 2- adrenoceptor blocker Selective noradrenaline re-uptake inhibitor irtazapine Tablet 15mg, 30mg, 45 mg Approved: major depression Reboxetine Tablet 4mg Approved: major depression ICE(CG90);(CG91);(CG38) ICE(CG90);(CG91);(CG38);(CG1 13) Tryptophan Tryptophan (L-Tryptophan) Tablet 500mg Approved- Restricted use: amed patient only for major depression ICE(CG90);(CG91);(CG38) Serotonin & noradrenaline re-uptake inhibitor (SRI) Venlafaxine Tablet 37.5mg, 75mg Tablet R 37.5mg, 75mg, 150mg, 225mg (Capsules R 75mg, 150mg) Approved: major depression; generalised anxiety disorder, social anxiety disorder Immediate release tablets should be prescribed 1 st line. /R tablets: Higher cost only use where specifically required (R capsules should not be prescribed ) ICE(CG90);(CG91);(CG38); (CG113) (CG159) TRUST EDICIES FORULARY_HA05_January 2017_V13

15 noradrenaline & dopamine reuptake inhibitor Duloxetine ot approved Bupropion R tablet 150mg, 300mg Approved: major depression (off-label) Consultant initiation only where ICE recommended treatments for mono or adjunctive therapy are ineffective or not tolerated. See Trust Antidepressant prescribing guidelines. elatonin agonist, serotonin antagonist Direct modulation of receptor activity & inhibition of serotonin transported Agomelatine ot approved (excluded from ICE guidance) Vortioxetine Tablet 5, 10, 20mg Approved: (3 rd line option) major depression (where inadequate response to 2 antidepressants within current episode) ICE(TA231) Terminated ICE TA CS stimulants and other drugs used for Attention Deficit Hyperactivity Disorder (ADHD) CS Stimulants ethylphenidate hydrochloride CD Dexamphetamine CD Lisdexamfetamine CD Tablet (immediate release) 5mg, 10mg Concerta XL tablets [22/78] 18mg, 27mg, 36mg Equasym XL capsules [30/70] 10mg, 20mg, 30mg edikinet XL capsules [50/50] 5mg, 10mg, 20mg, 30mg, 40mg 5mg tablets Capsulea 30mg, 50mg, 70mg Approved: Off-label use in adult (>18years) Attention deficit hyperactivity disorder (ADHD) Approved: (3 rd line option) Off-label use in adult (>18years) Attention deficit hyperactivity disorder (ADHD) Approved: (3 rd line option) Off-label use in adult (>18years) Attention deficit hyperactivity disorder (ADHD) XL preparations should be prescribed by specific brand name ICE(CG72); [ICE(TA98)] ICE(CG72); [ICE(TA98)] TRUST EDICIES FORULARY_HA05_January 2017_V13

16 on-cs Stimullants Atomoxetine Capsules 10mg, 18mg, 25mg, 40mg, 60mg Approved: Off-label use in adult (>18years) Attention deficit hyperactivity disorder (ADHD) ICE(CG72); [ICE(TA98)] 4.5 Drugs used in nausea & vertigo Hyoscine Hyoscine hydrobromide Chewable tablet (Kwells ) 300microgram Approved: Off-label treatment of clozapine induced hypersalivation 1.6 Laxatives Osmotic Lactulose Solution g/5ml Approved: treatment of clozapine induced laxatives constipation Antimuscarinic drugs used in parkinsonism Antimuscarinic drugs Orphenadrine rocyclidine Trihexyphenidyl (benzhexol hydrochloride) Tablet 50mg Liquid 50mg/ml Tablet 5mg Liquid 2.5mg/5ml Injection 5mg/ml Tablet 2mg, 5mg Liquid 5mg/ml Approved: parkinsonism; drug induced extrapyramidal symptoms Approved: parkinsonism; drug induced extrapyramidal symptoms Approved: parkinsonism; drug induced extrapyramidal symptoms, clozapine induced hypersalivation (off-label) ot tardive dyskinesia ot tardive dyskinesia ot tardive dyskinesia 4.10 Drugs used in substance dependence TRUST EDICIES FORULARY_HA05_January 2017_V13

17 Alcohol dependence Vitamin B group BF section Acamprosate Tablet 333mg Approved: maintenance of abstinence in alcohol dependence Chlordiazepoxide Capsule 5mg, 10mg Approved: alcohol detoxification Diazepam BF section4.1.2 Tablet 2mg, 5mg, 10mg Liquid 2mg/5ml, 5mg/5ml Approved: off-label use in alcohol detoxification; Oxazepam Tablet 10mg Approved: off-label use in alcohol detoxification; Disulfiram Tablet 200mg Approved: maintenance of abstinence in alcohol dependence altrexone Tablet 50mg Approved: aintenance of abstinence in alcohol dependence almefene Tablets Approved: Reduction of alcohol consumption Thiamine Tablets 50mg Approved: Treatment & prophylaxis of Wernicke/Korsakoff Vitamin B compound strong Tablets Approved: prophylactic supplement during detoxification abrinex I/ high potency injection Approved: Treatment & prophylaxis of Wernicke/Korsakoff SS only initiation ICE(CG115) ICE(CG115) ICE(CG115) For use when liver function significantly impaired SS only initiation ICE(CG115) SS only initiation ICE(CG115) SS initiation only ICE TA 325 ICE(CG100) ICE(CG100) Caution: anaphylaxis may occur following injection, facilities to treat must be available when administered. ICE(CG100) Benzodiazepine dependence Diazepam BF section4.1.2 Tablet 2mg, 5mg, 10mg Liquid 2mg/5ml, 5mg/5ml Approved: off-label use in benzodiazepine dependence icotine dependence icotine replacement therapy (RT) atches RT Lozenges atches 7mg, 14mg, 15mg, 21mg; 25mg Lozenge 1mg, 2mg, 4mg Approved: treatment for smoking cessation Restricted to inpatient and Community Smoking Cessation Team prescribing only for the treatment of smoking cessation. TRUST EDICIES FORULARY_HA05_January 2017_V13

18 RT Gum RT Inhaler RT asal Spray RT Oral spray Gum 1mg, 2mg, 4mg Inhaler 10mg, 15mg asal spray 500mcg Oral spray 1mg/metered dose ICE(H10) Varenicline Tablets 0.5mg, 1mg Approved: treatment for smoking cessation Trust guidance: ot recommended for acute inpatients ICE(H10);(TA123) Opioid Dependence Buprenorphine (Subutex ) CD Tablet sublingual 400microgram, 2mg, 8mg Approved: substitution treatment in opioid dependence Lofexidine Tablet 200 microgram Approved: management of symptoms in opioid detoxification ethadone CD orphine Sulphate odified Release CD BF section4.7.2 Oral solution sugar free, 1mg/ml Oral solution 1mg/ml Concentrated oral solution 10mg/ml Tablets 5mg Ampoules 10mg/1ml*, 35mg/3.5ml*, 50mg/5ml*, 50mg/1ml orphine sulphate R tablets 5mg, 10mg, 15mg, 30mg, 60mg, 100mg, 200mg Approved: substitution treatment in opioid dependence Approved Restricted use: off label use in substitution treatment in opioid dependence Approved- Restricted use (SS Consultant approval): off label* / substitution treatment in opioid dependence Approved Restricted use: Off-label use for detoxification in opioid dependence following chronic pain management. SS only initiation ICE(CG52);(TA114) SS only initiation ICE(CG52); SS only initiation or following Trust protocol: Opiate Addiction - anagement of hospital inpatients Concentrated oral solution (SS) restricted use only ICE(CG52);(TA114) SS only Restricted use only (travel where liquid volume an issue) ICE(TA114) SS Consultant only initiation * reparations not licensed for use in opioid dependence SS only initiation Restricted use only (jointly managed chronic pain clients) TRUST EDICIES FORULARY_HA05_January 2017_V13

19 Hypnotics BF section 4.11 Antispasmodics BF section 1.2 altrexone Tablet 50mg Approved: relapse prevention in opioid dependence Zopiclone Tablet 3.75mg, 7.5mg Approved: insomnia during opioid withdrawal ebeverine Tablet 135mg Approved: off label use for abdominal cramps due to opioid withdrawal Hyoscine butylbromide Tablet (Buscopan ) 10mg Approved: abdominal cramps due to opioid withdrawal SS only initiation ICE(TA115) Antimotility drugs BF section1.4.1 Drugs used in nausea & vertigo BF section 4.6 Analgesics BF section 4.7 SAID BF section Co-phenotrope Tablet 2.5/0.025 (diphenoxylate 2.5mg, atropine 25 microgram) Approved: diarrhoea due to opioid withdrawal Loperamide Tablet 2mg Approved: diarrhoea due to opioid withdrawal etoclopramide Tablet 10mg Approved: nausea & vomiting due to opioid withdrawal aracetamol Ibuprofen Tablets 500mg Dispersible tablets 500mg Tablets 200mg, 400mg, 600mg Approved: aches and pains due to opioid withdrawal Approved: aches and pains due to opioid withdrawal Dispersible tablets higher cost R tablet should not be prescribed higher cost Dexamphetamin e dependence Dexamphetamine CD Tablets 5mg Approved - Restricted use (Consultant Approval): Dexamphetamine detoxification SS Consultant only initiation Restricted use in patients previously prescribed and currently dependent on dexamphetamine Gamma-hydroxy butyrate (GHB) dependence Diazepam All oral preparations Approved: off-label use in treatment of GHB withdrawal symptoms Baclofen Tablets 10mg Approved: off-label use in treatment of GHB withdrawal symptoms TRUST EDICIES FORULARY_HA05_January 2017_V13

20 4.11 Drugs for Dementia Acetylcholinest erase inhibitors Donepezil Galantamine Rivastigmine Tablets 5mg, 10mg Tablet orodispersible 5mg, 10mg Tablet 8mg, 12mg Capsule R 8mg, 16mg, 24mg Solution 4mg/ml Capsule 1.5mg, 3mg, 4.5mg, 6mg atch 4.6mg/24hrs, 9.5mg/24hrs Approved (1 st line option): mild to moderate dementia in Alzheimer s disease, off-label use in severe dementia where continued benefit to treatment; off-label use for BSD in dementia with Lewy Body Approved (1 st line option): mild to moderate dementia in Alzheimer s disease, off-label use in severe dementia where continued benefit to treatment; off-label use for BSD in dementia with Lewy Body Approved (1 st line option): mild to moderate dementia in Alzheimer s disease, off-label use in severe dementia where continued benefit to treatment; off-label use for BSD in dementia with Lewy Body SAH initiation only ICE(CG42);(TA217) SAH initiation only ICE(CG42);(TA217) SAH initiation only ICE(CG42);(TA217) Glutamate antagonist emantine Tablets 10mg, 20mg Approved (2nd line option): moderate and severe dementia Alzheimer s disease where AChEI not tolerated or contraindicated. SAH initiation only ICE(CG42);(TA217) Antagonists for Central & Respiratory Depression Benzodiazepine antagonist Flumazenil Injection 100microgram/ml (5ml amp) Approved: off-label use for overdosage with benzodiazepines Slow intravenous injection ICE(CG25) Opioid antagonist aloxone Injection Approved: overdosage with opioids TRUST EDICIES FORULARY_HA05_January 2017_V13

South London and the Maudsley NHS Foundation Trust Medicines Formulary

South London and the Maudsley NHS Foundation Trust Medicines Formulary South London and the Maudsley NHS Foundation Trust Medicines Formulary Medicine Formulations Restrictions Additional Information / Related NICE Technology Appraisal 4.1 Hypnotics and anxiolytics 4.1.1

More information

This document has been produced in collaboration with the Lancashire Commissioning Support Unit

This document has been produced in collaboration with the Lancashire Commissioning Support Unit Joint for Psychotropic Medication. This document has been produced in collaboration with the Lancashire Commissioning Support Unit Date: December 2014. Reviewed August 2016. Next review Date April 2019

More information

Joint Formulary for Psychotropic Medication.

Joint Formulary for Psychotropic Medication. Joint for Psychotropic Medication. This document has been produced in collaboration with the Lancashire Commissioning Support Unit Page 1 Table of Contents Section Page Number Page 2 Definition of categories

More information

Safe transfer of prescribing guidance

Safe transfer of prescribing guidance Safe transfer of prescribing guidance TEWV Prescriber Summary Application required before prescribing Products requiring an application, before prescribing, using the single application form Unlicensed

More information

Medicines Formulary BNF Section 4 Central Nervous System

Medicines Formulary BNF Section 4 Central Nervous System Medicines BNF Section 4 4.1 Hypnotics and anxiolytics Chloral Hydrate 500mg/5ml Solution Clomethiazole 192mg Capsules Lormetazepam Tablets Melatonin Capsules Nitrazepam Suspension Nitrazepam Tablets Temazepam

More information

NSFT Formulary. Double Red Not recommended for routine use/not commissioned. These drugs have not been recommended for routine use at present.

NSFT Formulary. Double Red Not recommended for routine use/not commissioned. These drugs have not been recommended for routine use at present. Traffic Light Status NSFT Formulary Not recommended for routine use/not commissioned. These drugs have not been recommended for routine use at present. Hospital/Specialist only Drugs for which the Trust

More information

Formulary Item Restrictions and/or Advice Site availability

Formulary Item Restrictions and/or Advice Site availability Formulary Item Restrictions and/or Advice Site availability C&W CNWL Typical Antipsychotic drugs Chlorpromazine 25mg Chlorpromazine 50mg Chlorpromazine 100mg Chlorpromazine 25mg/5ml syrup Chlorpromazine

More information

Chapter 4 ~ Central nervous system

Chapter 4 ~ Central nervous system Chapter 4 ~ Central Nervous System: Special Section 1 of 5 Chapter 4 ~ Central nervous system 4.1 Hypnotics and anxiolytics 4.1.1 Hypnotics LOPRAZOLAM Tablet 1mg LORMETAZEPAM Tablet 500microgram PROMETHAZINE

More information

Introduction to Drug Treatment

Introduction to Drug Treatment Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical

More information

NI Formulary: Chapter 4 Central Nervous system

NI Formulary: Chapter 4 Central Nervous system Hypnotics Anxiolytics Acute state Non drug treatment Temazepam tablets 10mg, 20mg; oral solution 10mg/5ml or Zolpidem tablets 5mg, 10mg or Zopiclone 3.75mg, 7.5mg Non drug treatment Diazepam tablets 2mg,

More information

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: Prescribing and/ or Monitoring of Antipsychotics Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside

More information

Psychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI

Psychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT

More information

Preferred Prescribing Choices of Antipsychotic Drugs (APD) in Adults for Schizophrenia and Other Psychoses

Preferred Prescribing Choices of Antipsychotic Drugs (APD) in Adults for Schizophrenia and Other Psychoses Preferred Prescribing Choices of Antipsychotic Drugs (APD) in Adults for Schizophrenia and Other Psychoses HPFT Medicines Formulary lists the APDs that have been approved for use, however, it does not

More information

FORMULARY AND PRESCRIBING GUIDELINES 2017

FORMULARY AND PRESCRIBING GUIDELINES 2017 FORMULARY AND PRESCRIBING GUIDELINES 2017 1 Document Control Summary Issue Date Amended Section /page Author/ Amended by 1. Sept 06 All Jane Moriba Summary of Change Removed Trust policy and guideline

More information

PRESCRIBING GUIDELINES

PRESCRIBING GUIDELINES The Maudsley The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust PRESCRIBING GUIDELINES 10th Edition David Taylor Carol Paton Shitij Kapur informa healthcare Contents Authors

More information

Chapter 4 ~ Central nervous system

Chapter 4 ~ Central nervous system Chapter 4 ~ Central Nervous System: General Section 1 of 6 Chapter 4 ~ Central nervous system 4.1 Hypnotics and anxiolytics 4.1.1 Hypnotics CHLORAL HYDRATE CLOMETHIAZOLE NITRAZEPAM TEMAZEPAM TRICLOFOS

More information

CHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX

CHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX A Adderall Counterfeit, 31 addiction, internet CBT, 55 ADHD Adjunctive Guanfacine, 11 Counterfeit Adderall, 31 Developmental Trajectory and Risk Factors, 5 Dopamine Transporter Alterations, 14 Extended-Release

More information

Formulary and Prescribing Guidelines

Formulary and Prescribing Guidelines Formulary and Prescribing Guidelines SECTION 3: TREATMENT OF BIPOLAR AFFECTIVE DISORDER This section provides information regarding the pharmacological management of Bipolar affective disorder in secondary

More information

Treatment Options for Bipolar Disorder Contents

Treatment Options for Bipolar Disorder Contents Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8

More information

The Maudsley Prescribing Guidelines in

The Maudsley Prescribing Guidelines in The Maudsley Prescribing Guidelines in 11th Edition David Taylor Director of Pharmacy and Pathology South London and Maudsley NHS Foundation Trust; Professor King's College London, London, UK Paton Chief

More information

Answer ALL questions. For each question, there is ONE correct answer. Use the answer grid provided for ALL your answers.

Answer ALL questions. For each question, there is ONE correct answer. Use the answer grid provided for ALL your answers. CLINICAL THERAPEUTICS 7: PSYCHIATRY PHA-MHBY Time allowed: 2 hours UNIVERSITY OF EAST ANGLIA School of Pharmacy Main Series UG Examination 2013-2014 Part ONE Answer ALL questions. For each question, there

More information

FORMULARY AND PRESCRIBING GUIDELINES FOR CHILDREN AND ADOLESCENTS IN MENTAL HEALTH SERVICES

FORMULARY AND PRESCRIBING GUIDELINES FOR CHILDREN AND ADOLESCENTS IN MENTAL HEALTH SERVICES FORMULARY AND PRESCRIBING GUIDELINES FOR CHILDREN AND ADOLESCENTS IN MENTAL HEALTH SERVICES Version Control Summary Version Date Section(s) Author Comment(s)/Amendments 1 August 2008 All Sections Gbemi

More information

Manual of Clinical Psychopharmacology

Manual of Clinical Psychopharmacology Manual of Clinical Psychopharmacology Fourth Edition Alan F. Schatzberg, M.D. Kenneth T. Norris, Jr., Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School

More information

Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused

Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines

More information

Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services

Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services VIOLENCE, AGGRESSION OR SEVERE BEHAVIOURAL DISTURBANCE Introduction During an acute episode or illness, some

More information

SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS

SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS Formulary and Prescribing Guidelines 9.1 Introduction Movement disorders and extrapyramidal side effects can manifest in the

More information

PSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer

PSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally

More information

PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017

PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 NAME OF GUIDELINE REASON FOR GUIDELINE WHAT THE GUIDELINE WILL ACHIEVE? WHO NEEDS TO KNOW ABOUT IT? Medicines Guideline: Hypnotic Medication Compliance with NICE

More information

NSFT Formulary Contents Error! Bookmark not defined.

NSFT Formulary Contents Error! Bookmark not defined. NSFT Formulary Contents Traffic Light Status... 2 Clinical Commissioning Groups... 2 Typical Antipsychotics... 3 General Prescribing Information... 3 Atypical antipsychotics... 7 General Prescribing Information...

More information

ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY

ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100

More information

GUIDELINES FOR THE USE OF PSYCHOACTIVE MEDICATIONS IN INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDERS

GUIDELINES FOR THE USE OF PSYCHOACTIVE MEDICATIONS IN INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDERS City and County of San Francisco Mayor Gavin Newsom Department of Public Health Community Behavioral Health Services 1380 Howard Street 5 th Floor San Francisco, CA 94103 GUIDELINES FOR THE USE OF PSYCHOACTIVE

More information

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Effective: July. 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy

More information

T2/T3/S62/CT012 Aide Memoire

T2/T3/S62/CT012 Aide Memoire Correct way to fill out MHA forms T2/T3/S62/CTO12 SH CP 224 T2/T3/S62/CT012 Aide Memoire Version: 2 Summary: An Aide Memoire to completing or requesting a T2/T3/S62/CT012 Keywords: Target Audience: T2,

More information

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder

More information

Mental illness A Broad Overview. Dr H Pathmanandam March 2017

Mental illness A Broad Overview. Dr H Pathmanandam March 2017 Mental illness A Broad Overview Dr H Pathmanandam March 2017 Introduction Mental disorders are common in primary and secondary care Many are not recognised and not treated Some receive unnecessary or inappropriate

More information

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.

More information

West London Mental Health NHS Trust Formulary

West London Mental Health NHS Trust Formulary West London Mental Health NHS Trust Formulary VERSION 3.0 (18.02.15) The Formulary is a list of medicines used for mental health indications for patients cared for in all settings of West London Mental

More information

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution

More information

Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services

Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services DRIVING AND MENTAL HEALTH CONDITIONS AND TREATMENTS General information Driving while impaired by a physical

More information

West London Mental Health NHS Trust Formulary

West London Mental Health NHS Trust Formulary West London Mental Health NHS Trust Formulary VERSION 7.0 (09.11.16) The Formulary is a list of medicines used for mental health indications for patients cared for in all settings of West London Mental

More information

Drugs used for the treatment of depression Selective Serotonin Reuptake Inhibitors Tricyclic and related antidepressants Others antidepressants

Drugs used for the treatment of depression Selective Serotonin Reuptake Inhibitors Tricyclic and related antidepressants Others antidepressants Central Nervous System Drugs used for the treatment of depression Anxiolytics and hypnotics Drugs used in psychosis and related disorders Drugs used in substance dependence for patients with established

More information

IMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members

IMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members IMPORTANT NOTICE Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members These changes apply only to members covered under the DC Healthcare Alliance program Alliance

More information

NSFT Formulary Contents

NSFT Formulary Contents NSFT Formulary Contents Traffic Light Status... 2 Clinical Commissioning Groups... 2 Antipsychotics... 3 General Prescribing Information... 3 Typical Antipsychotics... 5 Atypical antipsychotics... 10 General

More information

NSFT Formulary Contents

NSFT Formulary Contents NSFT Formulary Contents Traffic Light Status... 2 Clinical Commissioning Groups... 2 Antipsychotics... 3 General Prescribing Information... 3 Typical Antipsychotics... 5 Atypical antipsychotics... 9 General

More information

Psychotropic Drug Therapy in Adults with Learning Disability. Steve Wilkinson

Psychotropic Drug Therapy in Adults with Learning Disability. Steve Wilkinson Psychotropic Drug Therapy in Adults with Learning Disability Steve Wilkinson Outline and Aims of the Session Drug use in learning disability Two distinct areas of drug therapy I. Treatment of common psychiatric

More information

Guidelines on Choice and Selection of Antipsychotics for the Management of Psychosis and Schizophrenia in Adults

Guidelines on Choice and Selection of Antipsychotics for the Management of Psychosis and Schizophrenia in Adults Working in partnership: Hertfordshire Partnership University NHS Foundation Trust East and North Hertfordshire Clinical Commissioning Group Herts Valleys Clinical Commissioning Group Guidelines on Choice

More information

Medications and Children Disorders

Medications and Children Disorders Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for

More information

Medicines used in Mental Health

Medicines used in Mental Health Publication Report Medicines used in Mental Health Years 24/5 to 214/15 Publication date 13 October 215 A National Statistics Publication for Scotland Contents Introduction... 2 Hypnotics & Anxiolytics...

More information

PSYCHIATRY DRUG ALERTS, VOLUME XXVIII, 2014 INDEX

PSYCHIATRY DRUG ALERTS, VOLUME XXVIII, 2014 INDEX A acamprosate ADHD Generic Methylphenidate Equivalence, 84 Methylphenidate in Pregnancy, 9 Stimulants in Pregnancy, 50 adverse effects Antidepressant-Induced Jitteriness, 94 Antidepressants and Sexual

More information

Stop smoking products guidance

Stop smoking products guidance Stop smoking products guidance Ref: Status: Approved Stop smoking products guidance Page 1 of 15 Approval date: 22 November 2018 Contents 1. Purpose... 3 2. Related documents... 3 3. Guidance... 3 3.1

More information

Index. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers

Index. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic

More information

NSFT Formulary Contents

NSFT Formulary Contents NSFT Formulary Contents Traffic Light Status... 2 Clinical Commissioning Groups... 2 Antipsychotics... 3 General Prescribing Information... 3 Typical Antipsychotics... 5 Atypical antipsychotics... 10 General

More information

FORMULARY AND PRESCRIBING GUIDANCE

FORMULARY AND PRESCRIBING GUIDANCE FORMULARY AND PRESCRIBING GUIDANCE GUIDELINE VERSION 18 RATIFYING GROUP Drugs and Therapeutics Group (DTG) DATE PUBLISHED NEXT REVIEW DATE (see specific guidelines) FORMULARY SPONSOR Executive Medical

More information

Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs

Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs (Version 3 January 2015) Principal Author: Dr Jenny Cooke Consultant Psychiatrist, Brighton & Hove Perinatal Mental Health Service

More information

Psychotropic Medication Use in Dementia

Psychotropic Medication Use in Dementia Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,

More information

Adverse events of common psychiatric medications: an umbrella review

Adverse events of common psychiatric medications: an umbrella review Adverse events of common psychiatric medications: an umbrella review Katrina Bartellas, 1 Thomas Bajorek 1 Sarah Stockton, 1 Stefan Leucht, 2 Andrea Cipriani, 1 Seena Fazel 1 1 Department of Psychiatry,

More information

Guide to Psychiatric Medications for Children and Adolescents

Guide to Psychiatric Medications for Children and Adolescents Guide to Psychiatric Medications for Children and Adolescents by Glenn S. Hirsch, M.D. The following guide includes most of the medications used to treat child and adolescent mental disorders. It lists

More information

Things You Might Not Know About Psychotropic Medications But Wish You Did

Things You Might Not Know About Psychotropic Medications But Wish You Did Things You Might Not Know About Psychotropic Medications But Wish You Did John E. Dunne, MD December 3, 2016 PAL Conference Conflicts of Interest None to report I am employed by Seattle Children s and

More information

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17

More information

Smoking Cessation Pharmacotherapy Guidelines

Smoking Cessation Pharmacotherapy Guidelines Smoking Cessation Pharmacotherapy Guidelines INTRODUCTION This guideline is based on public health guidance 10 Smoking Cessation Services issued by the National Institute for Health and Clinical Excellence

More information

MEDICATION ALGORITHM FOR ANXIETY DISORDERS

MEDICATION ALGORITHM FOR ANXIETY DISORDERS Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON

More information

Document Title Pharmacological Management of Generalised Anxiety Disorder

Document Title Pharmacological Management of Generalised Anxiety Disorder Document Title Pharmacological Management of Generalised Anxiety Disorder Document Description Document Type Policy Service Application Trust Wide Version 1.1 Policy Reference no. POL 201 Lead Author(s)

More information

Medicines used in Mental Health

Medicines used in Mental Health Publication Report Medicines used in Mental Health Years 26/7 to 216/17 Publication date 1 October 217 A National Statistics Publication for Scotland Contents Introduction... 2 Hypnotics & Anxiolytics...

More information

DISEASES AND DISORDERS

DISEASES AND DISORDERS DISEASES AND DISORDERS 13. The mood (affective) disorders 99 14. The psychotic disorders: schizophrenia 105 15. The anxiety and somatoform disorders 111 16. Dementia and delirium 117 17. Alcohol and substance-related

More information

Pediatric Psychopharmacology

Pediatric Psychopharmacology Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders

More information

Antipsychotics. Something Old, Something New, Something Used to Treat the Blues

Antipsychotics. Something Old, Something New, Something Used to Treat the Blues Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer

More information

Antidepressants. Dr Malek Zihlif

Antidepressants. Dr Malek Zihlif Antidepressants The optimal use of antidepressant required a clear understanding of their mechanism of action, pharmacokinetics, potential drug interaction and the deferential diagnosis of psychiatric

More information

Mixing and Matching: Layering Medications as Family Physicians

Mixing and Matching: Layering Medications as Family Physicians Mixing and Matching: Layering Medications as Family Physicians Family Medicine Forum Vancouver, B.C. November 9-12, 2016. Jon Davine, CCFP, FRCP(C) McMaster University Objectives Discuss different examples

More information

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services ANXIETY DISORDERS This guideline covers a range of anxiety disorders, including generalised anxiety disorder, social

More information

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral

More information

Psychiatric Medication Guide

Psychiatric Medication Guide Psychiatric Medication Guide F O R : N E O N P R I M A R Y H E A L T H C A R E P R O V I D E R S B Y : M I C H E L L E R O M E R O, D O M A Y, 2 0 1 3 Anti-depressants TCA s & MAOI s (Tricyclic Antidepressants

More information

Introduction to psychotropic medications JAYNE CAMPBELL

Introduction to psychotropic medications JAYNE CAMPBELL Introduction to psychotropic medications JAYNE CAMPBELL Introduction Psychotropic medications are prescription drugs that are commonly used to control some symptoms associated with many different types

More information

COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications*

COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications* COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications* Bupropion (Wellbutrin) Start: IR-100 mg bid X 4d then to 100 mg tid; SR-150

More information

Psychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis

Psychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis Psychiatric Illness In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis 12,000,000 children infants through 18 y/o nation wide 5,000,000 suffer severely Serious

More information

NorthSTAR. Pharmacy Manual

NorthSTAR. Pharmacy Manual NorthSTAR Pharmacy Manual Revised October, 2008 Table of I. Introduction II. III. IV. Antidepressants New Generation Antipsychotic Medications Mood Stabilizers V. ADHD Medications VI. Anxiolytics and Sedative-Hypnotics

More information

Professor David Castle. Ms. Nga Tran. St. Vincent s Mental Health Level 2, 46 Nicholson Street, Fitzroy Vic 3065

Professor David Castle. Ms. Nga Tran. St. Vincent s Mental Health Level 2, 46 Nicholson Street, Fitzroy Vic 3065 ARABIIC Professor David Castle Ms. Nga Tran St. Vincent s Mental Health Level 2, 46 Nicholson Street, Fitzroy Vic 3065 (03) 9288 4147 (03) 9288 4751 Psychiatric Medication Information / Arabic 1 Psychiatric

More information

Schedule FDA & literature based indications

Schedule FDA & literature based indications Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for

More information

PRESCRIBING PRACTICE IN DELIRIUM. John Warburton Critical Care Pharmacist

PRESCRIBING PRACTICE IN DELIRIUM. John Warburton Critical Care Pharmacist PRESCRIBING PRACTICE IN DELIRIUM John Warburton Critical Care Pharmacist Learning outcomes Modifiable medication risk factors for delirium An appreciation of contributing factors modifiable with medicines

More information

Psychobiology Handout

Psychobiology Handout Nsg 85A / Psychiatric Page 1 of 7 Psychobiology Handout STRUCTURE AND FUNCTION OF THE BRAIN Psychiatric illness and the treatment of psychiatric illness alter brain functioning. Some examples of this are

More information

Medicine Related Falls Risk Assessment Tool (MRFRAT)

Medicine Related Falls Risk Assessment Tool (MRFRAT) Medicine Related Falls Risk Assessment Tool (MRFRAT) The Medicine Related Falls Risk Assessment tool (MRFRAT) in Appendix 1 is designed to help identify patients at risk of falls due to their current medicine

More information

Mood Disorders.

Mood Disorders. Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner

More information

This factsheet covers:

This factsheet covers: Antipsychotics If you experience psychosis as part of your illness, you may be offered antipsychotic medication. Antipsychotics are generally used to treat psychosis, but are also used to treat bipolar

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine

More information

CHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XV, 2013 INDEX

CHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XV, 2013 INDEX A acceptance and commitment therapy Posttraumatic Stress, 69 ADHD Adjunctive Fatty Acids, 5 Adjunctive Guanfacine Pharmacokinetics, 27 Amantadine, 21 Atomoxetine, 23 Cancer Risk, 31 CBT for Comorbid Anxiety,

More information

SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]

SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance] SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm

More information

Medically Accepted Indications for Pediatric Use of Psychotropic Medications by

Medically Accepted Indications for Pediatric Use of Psychotropic Medications by Key: White Background: Medically Accepted Indication Yellow Backgroun: Medically Accepted Indication Status Not Ascertained Orange Background: Pediatric Indication cited, but not supported Red Background:

More information

Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015)

Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1. Key Points Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1.1 Olanzapine long acting injection (LAI) is indicated for the maintenance

More information

Antidepressant Treatment of Depression

Antidepressant Treatment of Depression Antidepressant Treatment of Depression PLEASE REFER TO INTEGRATED CARE PATHWAY FOR INFORMATION RELATING TO THE OVERALL MANAGEMENT OF DEPRESSION SSRI s are first choice agents because they are as effective

More information

Index. Index. More information

Index. Index. More information acamprosate, alcohol dependence, 223 225, 227 228, 252 acetylcholine, role in Alzheimer s disease, 263 aerobic exercise, panic disorder, 81 agitation, schizophrenia sedation strategies, 21 agomelatine,

More information

Antipsychotics. BMF 84 - Antipsychotics

Antipsychotics. BMF 84 - Antipsychotics Antipsychotics BMF 84 - Antipsychotics Antipsychotic medications (neuroleptics) are used for the treatment of psychosis, mainly schizophrenia and manic depression (bipolar disorder). They reduce symptoms

More information

Medicine Related Falls Risk Assessment Tool (MrFRAT) User Guide for Age Related Residential Care Facility Staff in Hawke s Bay

Medicine Related Falls Risk Assessment Tool (MrFRAT) User Guide for Age Related Residential Care Facility Staff in Hawke s Bay Medicine Related Falls Risk Assessment Tool (MrFRAT) User Guide for Age Related Residential Care Facility Staff in Hawke s Bay (Revised edition November 2015) The Medicine Related Falls Risk Assessment

More information

3. IC50 represents the concentration of antagonist needed to displace the ligand from 50% of the available receptors.

3. IC50 represents the concentration of antagonist needed to displace the ligand from 50% of the available receptors. Paper 2 True False Ouestions ~ 1. Tubocurarine is a nicotinic receptor antagonist. 2. In a dose-response curve ED50 represents the dose which elicits 50% of the maximal response and Emax represents the

More information

DEMENTIA AND MEDICATION

DEMENTIA AND MEDICATION DEMENTIA AND MEDICATION Dr. Siobhan Ni Bhriain, MRCP, MRCPsych. Clinical Director, Tallaght and SJH MHS, Consultant Old Age Psychiatrist, Chair, DSIDC Steering Committee. SUMMARY OF TODAY S TALK Dementia-definition,

More information

SMOKING AND DRUG INTERACTIONS

SMOKING AND DRUG INTERACTIONS Medicines Information Centre Pharmacy Department UK Medicines Information SMOKING AND DRUG INTERACTIONS Introduction Smoking rates are significantly higher among people with mental health problems. It

More information

Pharmacological Treatment of Anxiety & Depressive Disorders

Pharmacological Treatment of Anxiety & Depressive Disorders Pharmacological Treatment of Anxiety & Depressive Disorders Dr Gary Jackson (MB BCh FRCPsych) Consultant Psychiatrist The Priory Hospital Chelmsford Wellesley Hospital Southend-on-Sea Medical Secretary:

More information

Medication management of anxiety & depression. Dr Katie Simpson GP Mental health lead East Berks CCG

Medication management of anxiety & depression. Dr Katie Simpson GP Mental health lead East Berks CCG Medication management of anxiety & depression Dr Katie impson GP Mental health lead East Berks CCG NICE guidelines for Anxiety tepped Care RIs and NRIs in Anxiety disorders RI ertraline Citalopram Fluoxetine

More information